Corbus Pharmaceuticals Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Corbus Pharmaceuticals Holdings, Inc. (CRBP) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value of $437.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $437.00K.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $227.00K.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $108.00.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $658.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value |
|---|---|
| 2026-06-30 | $437.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $227.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $108.00 10-K · filed 2026-03-09 |
| 2025-09-30 | $658.00 10-Q · filed 2025-11-12 |
| 2025-06-30 | $145.00 10-Q · filed 2025-08-05 |
| 2025-03-31 | $53.00 10-Q · filed 2025-05-06 |
| 2024-12-31 | $388.00K 10-K · filed 2025-03-11 |
| 2024-09-30 | $1.20M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $3.46M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $3.97M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $6.24M 10-K · filed 2024-03-12 |
| 2023-09-30 | $5.73M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $5.25M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $5.05M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $3.18M 10-K · filed 2023-03-07 |
| 2022-09-30 | $3.06M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $2.71M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $2.64M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $2.69M 10-K · filed 2022-03-08 |
| 2021-09-30 | $2.71M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $2.71M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $2.76M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $3.42M 10-K · filed 2021-03-15 |
| 2020-09-30 | $3.60M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $52.29M 10-Q/A · filed 2020-08-31 |
| 2020-03-31 | $20.67M 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |